Research programme: melanocortin analogues - Clinuvel PharmaceuticalsAlternative Names: CUV9900; VLRX 001
Latest Information Update: 11 Jun 2015
At a glance
- Originator University of Arizona
- Class Hormones; Peptides; Skin disorder therapies
- Mechanism of Action Melanocyte stimulating hormone stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin disorders; Vitiligo
Most Recent Events
- 05 May 2015 Preclinical trials in Vitiligo in Australia (Topical)
- 19 Sep 2014 Preclinical development in Skin disorders is ongoing in Australia